Skip to content
Screener

Pre-Tax Income at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$61.38M-79.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%
RFL
Rafael Holdings, Inc.RFL
-$2.89M+55.2%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.66M+1.3%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$6.47M+54.2%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.57M+205%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+7.3%
Enterprise value$561.65M-17.1%
P/E12.1×-237×
P/S5.2×-5.4×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Fair value adjustment related to investments(140)(2)(356)(5)
Interest and other income, net2,5652,3786,1552,921
Total other (expense) income(3,983)147,945(11,324)151,390
Income before income taxes12,79476,90657,59974,989
Income tax expense(4,042)(2,199)(10,957)(3,381)
Net income$8,752$74,707$46,642$71,608
Net income per share of common stock:
Basic$0.14$1.24$0.76$1.20

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s pre-tax income?
Zevra Therapeutics, Inc. (ZVRA) reported pre-tax income of $12.79M in Q2 2026.
How has Zevra Therapeutics, Inc.'s pre-tax income changed year-over-year?
Zevra Therapeutics, Inc.'s pre-tax income decreased by 83.4% year-over-year, from $76.91M to $12.79M.
What is the long-term trend for Zevra Therapeutics, Inc.'s pre-tax income?
Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s pre-tax income has grown at a 116.7% compound annual growth rate (CAGR), from -$8.52M to $86.68M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Zevra Therapeutics, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude